Klus Pharma to Attend the ADC & Radiopharmaceuticals Pharma and Biotech Partnering Summit

Klus Pharma will attend the ADC & Radiopharmaceuticals Pharma and Biotech Partnering Summit held in Boston, MA from September 9-10, 2024. The event provides a focused meeting platform for attendees from more than 100+ prominent ADC and related companies to share and discuss their perspectives, interests, and recent developments within the field. With the growing interest and recent deal-making activities in the ADC field, we are keen to explore potential partnering opportunities with interested parties and feel free to schedule a meeting with us through the One-on-One Partnering platform.

Klus Pharma is the US subsidiary of Kelun-Biotech, an innovative China-based drug developer that has become a well-recognized and major player in the ADC field through its recent collaborations with Merck (known as MSD outside the United States and Canada) for several ADC candidates. Since the inception of Kelun-Biotech in 2016, the Company has steadily built up its own proprietary ADC platform, OptiDC, which is based on irreversible conjugation chemistry, highly stable and adjustable linkers, and a novel topoisomerase-I inhibitor payload with bystander effect. Leveraging this platform alongside our talented team of scientists and clinicians has allowed the creation of more than ten promising ADC molecules, four of which are being advanced in ongoing clinical trials: sacituzumab tirumotecan (TROP2 ADC), A166 (HER2 ADC), SKB315 (Claudin 18.2 ADC), and SKB410 (Nectin-4 ADC).

In addition, several "next-generation" ADC candidates are undergoing preclinical studies, which includes testing of various linker-payload strategies and antibody formats. We would also be interested in exploring the potential of developing new ADC candidates with companies that have novel antibodies, linker-payload strategies, and/or other ADC-enhancing technologies.